Table 3.
Comparison of patient, tumor, and treatment-related characteristics between patients who experienced and did not experience phantosmia
| No phantosmia | Phantosmia | |||
|---|---|---|---|---|
| n = 87 (%) | n = 12 (%) | P value | ||
| Age, y, median (range) | 19 (2-39) | 17 (12-33) | .771 | |
| Gender | Female | 35 (40.2) | 4 (33.3) | .886 |
| Male | 52 (59.8) | 8 (66.7) | ||
| ECOG | 0 | 48 (55.2) | 8 (66.7) | .862 |
| 1 | 18 (20.7) | 2 (16.7) | ||
| 2 | 6 (6.9) | 0 (0.0) | ||
| 3 | 1 (1.1) | 0 (0.0) | ||
| Unknown | 14 (16.1) | 2 (16.7) | ||
| Primary tumor histology | Medulloblastoma | 10 (11.5) | 4 (33.3) | .072 |
| Rhabdomyosarcoma | 13 (14.9) | 0 (0.0) | ||
| Low grade glioma | 10 (11.5) | 1 (8.3) | ||
| High-grade glioma | 9 (10.3) | 1 (8.3) | ||
| Germinoma | 4 (4.6) | 4 (33.3) | ||
| Ependymoma | 5 (5.7) | 0 (0.0) | ||
| Nasopharyngeal Carcinoma | 5 (5.7) | 0 (0.0) | ||
| Meningioma | 3 (3.4) | 0 (0.0) | ||
| Neuroblastoma | 3 (3.4) | 0 (0.0) | ||
| Oligodendroglioma | 3 (3.4) | 0 (0.0) | ||
| Pituitary adenoma | 3 (3.4) | 0 (0.0) | ||
| Pleomorphic Xanthoastrocytoma | 3 (3.4) | 0 (0.0) | ||
| Other | 16 (18.4) | 2 (16.7) | ||
| Disease | Primary | 62 (71.3) | 11 (91.7) | .317 |
| Recurrent | 23 (26.4) | 1 (8.3) | ||
| Metastatic | 2 (2.3) | 0 (0.0) | ||
| Tumor location | Intracranial | 53 (60.9) | 11 (91.7) | .197 |
| Skull base | 15 (17.2) | 1 (8.3) | ||
| Nasopharyngeal | 12 (13.8) | 0 (0.0) | ||
| Sinonasal | 7 (8.0) | 0 (0.0) | ||
| Prior RT | No | 77 (88.5) | 12 (100.0) | .467 |
| Yes | 10 (11.5) | 0 (0.0) | ||
| Radiation alone | No | 76 (87.4) | 12 (100.0) | .414 |
| Yes | 11 (12.6) | 0 (0.0) | ||
| Other treatment | Chemotherapy | 23 (26.4) | 2 (16.7) | .416 |
| Surgery | 24 (27.6) | 5 (41.7) | ||
| Chemotherapy and surgery | 29 (33.3) | 5 (41.7) | ||
| None | 11 (12.6) | 0 (0.0) | ||
| Use of chemotherapy concurrently or before RT | No | 38 (43.7) | 5 (41.7) | 1 |
| Yes | 49 (56.3) | 7 (58.3) | ||
| Seizures before/during RT | No | 76 (87.4) | 10 (83.3) | 1 |
| Yes | 11 (12.6) | 2 (16.7) | ||
| Concurrent use of antiepileptics | No | 71 (81.6) | 8 (66.7) | .409 |
| Yes | 16 (18.4) | 4 (33.3) | ||
| Acute toxicity, grade 2 or higher | No | 46 (52.9) | 6 (50.0) | 1 |
| Yes | 41 (47.1) | 6 (50.0) | ||
| Radiation field | Partial brain | 69 (79.3) | 4 (33.3) | .002 |
| Whole brain | 18 (20.7) | 8 (66.7) | ||
| Craniospinal irradiation | No | 69 (79.3) | 4 (33.3) | .002 |
| Yes | 18 (20.7) | 8 (66.7) | ||
| RT cumulative dose, Gy CGE, median (range) | 46 (14.8-74) | 23.4 (18-54) | .001 | |
| RT dose per fraction, Gy CGE, median (range) | 1.8 (1.5-3.7) | 1.8 (1.8-1.8) | .239 | |
Abbreviations: CGE = cobalt gray equivalent; ECOG = Eastern Cooperative Oncology Group; RT = radiation therapy.